Determination of the Activity of Standard Anti-tuberculosis Drugs Against Intramacrophage Mycobacterium Tuberculosis, in Vitro: MGIT 960 As a Viable Alternative for BACTEC 460

Overview

Journal Braz J Infect Dis

Specialty Infectious Diseases

Date 2014 Apr 9

PMID 24709416

Citations 3

Authors

Sarbjit Singh Jhamb

Amit Goyal

Prati Pal Singh

Affiliations

Soon will be listed here.

Abstract

BACTEC 460 has now been phased out, so the search for an alternative is imperative. We have determined the activity of standard anti-tuberculosis drugs against intramacrophage Mycobacterium tuberculosis, in vitro, by using BACTEC 460 and MGIT 960 methods. The minimum inhibitory concentrations of isoniazid, rifampicin, ethambutol and streptomycin against intracellular M. tuberculosis H37Rv were found to be 0.2, 0.8, 8.0, and 5.0 μg/mL, respectively, by both methods. These results show a significant (p<0.001) concordance between minimum inhibitory concentrations obtained by these two different methods. MGIT 960 system uses a robust florescence quenching-based oxygen sensor, requires no radioisotope, is safe, and relatively easy to operate. Apparently, this is the first report wherein MGIT 960 has been validated for anti-tubercular susceptibility testing against intracellular M. tuberculosis H37Rv. Our preliminary data thus clearly demonstrate that the MGIT 960 method can be considered as a promising alternative to BACTEC 460 method.

Citing Articles

Development of Human Cell-Based Infection Models to Determine the Intracellular Survival of .

Kilinc G, Walburg K, Franken K, Valkenburg M, Aubry A, Haks M Front Cell Infect Microbiol. 2022; 12:872361.

PMID: 35811670 PMC: 9263196. DOI: 10.3389/fcimb.2022.872361.

Computational modeling and bioinformatic analyses of functional mutations in drug target genes in .

Singh P, Jamal S, Ahmed F, Saqib N, Mehra S, Ali W Comput Struct Biotechnol J. 2021; 19:2423-2446.

PMID: 34025934 PMC: 8113780. DOI: 10.1016/j.csbj.2021.04.034.

Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets Determination.

Ali A, Lee Y, Chen T, Chen C, Lee C, Shiau C PLoS One. 2016; 11(4):e0154278.

PMID: 27100886 PMC: 4839570. DOI: 10.1371/journal.pone.0154278.

References

Bemer P, Palicova F, Rusch-Gerdes S, Drugeon H, Pfyffer G . Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2002; 40(1):150-4. PMC: 120114. DOI: 10.1128/JCM.40.1.150-154.2002. View

Toungoussova O, Mariandyshev A, Bjune G, Caugant D, Sandven P . Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur J Clin Microbiol Infect Dis. 2005; 24(3):202-6. DOI: 10.1007/s10096-005-1284-z. View

Parida S . True facets of TB diagnosis in 2012: Hypes and realities. Eur J Microbiol Immunol (Bp). 2013; 2(4):275-81. PMC: 3832067. DOI: 10.1556/EuJMI.2.2012.4.5. View

Jhamb S, Singh R, Singh P . A comparison of conventional and radiometric methods for the assessment of anti-tubercular activity of drugs against Mycobacterium tuberculosis in mice and macrophage models. Indian J Tuberc. 2008; 55(2):70-6. View

Huang T, Tu H, Shin-Jung Lee S, Huang W, Liu Y . Antimicrobial susceptibility testing of Mycobacterium tuberculosis to first-line drugs: comparisons of the MGIT 960 and BACTEC 460 systems. Ann Clin Lab Sci. 2002; 32(2):142-7. View

Bryskier A, Drugeon H . Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother. 2000; 46(4):571-6. DOI: 10.1093/jac/46.4.571. View

Somoskovi A, Kodmon C, Lantos A, Bartfai Z, Tamasi L, Fuzy J . Comparison of recoveries of mycobacterium tuberculosis using the automated BACTEC MGIT 960 system, the BACTEC 460 TB system, and Löwenstein-Jensen medium. J Clin Microbiol. 2000; 38(6):2395-7. PMC: 86818. DOI: 10.1128/JCM.38.6.2395-2397.2000. View

Jagannath C, Reddy M, Kailasam S, OSullivan J, GANGADHARAM P . Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med. 1995; 151(4):1083-6. DOI: 10.1164/ajrccm/151.4.1083. View

Lonnroth K, Castro K, Chakaya J, Chauhan L, Floyd K, Glaziou P . Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010; 375(9728):1814-29. DOI: 10.1016/S0140-6736(10)60483-7. View

10.

Kaur S, Kaur H, Singh P . Induction of colony-stimulating factors by a 30-kDa secretory protein of Mycobacterium tuberculosis H37Rv. Eur Cytokine Netw. 2005; 15(4):327-38. View

11.

Huang T, Shin-Jung Lee S, Tu H, Huang W, Chen Y, Huang C . Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide. J Antimicrob Chemother. 2004; 53(4):600-3. DOI: 10.1093/jac/dkh120. View

12.

Duman N, Cevikbas A, Johansson C . The effects of rifampicin and fluoroquinolones on tubercle bacilli within human macrophages. Int J Antimicrob Agents. 2004; 23(1):84-7. DOI: 10.1016/j.ijantimicag.2003.05.017. View

13.

Adjers-Koskela K, Katila M . Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis. J Clin Microbiol. 2003; 41(3):1235-9. PMC: 150305. DOI: 10.1128/JCM.41.3.1235-1239.2003. View

14.

Abdel Aziz M, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A . Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006; 368(9553):2142-54. DOI: 10.1016/S0140-6736(06)69863-2. View

15.

Rastogi N, Labrousse V, Bryskier A . Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother. 1995; 39(4):976-8. PMC: 162664. DOI: 10.1128/AAC.39.4.976. View

16.

Balabanova Y, Ruddy M, Hubb J, Yates M, Malomanova N, Fedorin I . Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis. 2005; 24(2):136-9. DOI: 10.1007/s10096-004-1268-4. View

17.

Dhillon J, Mitchison D . Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254. Antimicrob Agents Chemother. 1989; 33(8):1255-9. PMC: 172636. DOI: 10.1128/AAC.33.8.1255. View

18.

GANGADHARAM P, Perumal V, Podapati N, Kesavalu L, Iseman M . In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother. 1988; 32(9):1400-3. PMC: 175876. DOI: 10.1128/AAC.32.9.1400. View

19.

Salfinger M, Pfyffer G . The new diagnostic mycobacteriology laboratory. Eur J Clin Microbiol Infect Dis. 1994; 13(11):961-79. DOI: 10.1007/BF02111498. View